Skip to main content
Premium Trial:

Request an Annual Quote

Chronix Nabs $1.8M in Series E Funding

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chronix Biomedical said today that it has reeled in $1.8 million in Series E financing from existing and new investors that it is using to develop its serum-based disease tests.

The company's testing technology uses disease-specific biomarkers based on DNA fragments from damaged and dying cells that circulate in the bloodstream and are applicable to a range of cancers and other diseases.

"Funds from this financing helped us complete proof-of-concept studies confirming that our apoptotic DNA blood tests can accurately detect multiple cancers at early stages," and which resulted in two patent filings for tests for breast and prostate cancer, Chronix CEO Howard Urnovitz said in a statement.

Chronix's two lead assays have detected breast cancer and invasive prostate cancer with 92 percent sensitivity and 100 percent specificity in "a number of peer-reviewed settings," the San Jose, Calif.-based firm said.

Other studies have shown that the company's DNA-based biomarker technology can identify the presence or absence of active disease in multiple sclerosis patients, and that it can detect early-stage breast cancer, Chronix said.

The company also is working with the University of Calgary to develop a veterinary test for detecting mad cow disease.

"In view of the multiple potential applications for our technology, we have now initiated a significantly larger financing that will be used to accelerate the commercialization process," added company CFO John DiPietro. "Our returning shareholders have participated in each round of financing to date based upon Chronix having successfully achieved our stated milestones, and the closing of this Series E round will allow us to complete the remainder of the milestones we have mapped out for the coming year."

The company also is offering its Apoptic Serum DNA testing service to cancer researchers for investigational use only to track disease recurrence in clinical trials.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.